Fulcrum Therapeutics (NASDAQ:FULC) Cut to Market Perform at Leerink Partners

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by equities research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report issued on Tuesday, MarketBeat.com reports. They presently have a $4.00 price objective on the stock. Leerink Partners’ price objective indicates a potential downside of 37.69% from the stock’s current price.

Other equities analysts have also issued research reports about the company. Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective on the stock. in a research note on Tuesday. Piper Sandler lowered Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a research note on Tuesday. HC Wainwright lowered Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research note on Tuesday. Truist Financial set a $4.00 price target on Fulcrum Therapeutics and gave the company a “hold” rating in a research note on Tuesday. Finally, Wall Street Zen raised Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.20.

Fulcrum Therapeutics Stock Performance

Shares of FULC opened at $6.42 on Tuesday. Fulcrum Therapeutics has a one year low of $5.88 and a one year high of $15.74. The stock has a market capitalization of $427.78 million, a price-to-earnings ratio of -5.58 and a beta of 3.02. The stock has a 50 day moving average price of $7.23 and a 200 day moving average price of $9.22.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. On average, analysts predict that Fulcrum Therapeutics will post -1.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Suvretta Capital Management LLC increased its holdings in shares of Fulcrum Therapeutics by 21.9% in the 4th quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company’s stock valued at $74,206,000 after acquiring an additional 1,180,111 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in shares of Fulcrum Therapeutics by 8.9% in the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock valued at $42,971,000 after acquiring an additional 382,485 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Fulcrum Therapeutics by 53.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock valued at $31,572,000 after acquiring an additional 1,589,000 shares during the last quarter. Braidwell LP increased its holdings in shares of Fulcrum Therapeutics by 1,294.7% in the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock valued at $34,622,000 after acquiring an additional 2,841,734 shares during the last quarter. Finally, Siren L.L.C. increased its holdings in shares of Fulcrum Therapeutics by 20.5% in the 1st quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock valued at $18,024,000 after acquiring an additional 400,000 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.